Your browser doesn't support javascript.
loading
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp, Andrew R; James, Elizabeth C; McNeish, Iain A; Dean, Andrew; Kim, Jae-Weon; O'Donnell, Dearbhaile M; Hook, Jane; Coyle, Christopher; Blagden, Sarah; Brenton, James D; Naik, Raj; Perren, Tim; Sundar, Sudha; Cook, Adrian D; Gopalakrishnan, Gosala S; Gabra, Hani; Lord, Rosemary; Dark, Graham; Earl, Helena M; Hall, Marcia; Banerjee, Susana; Glasspool, Rosalind M; Jones, Rachel; Williams, Sarah; Swart, Ann Marie; Stenning, Sally; Parmar, Mahesh; Kaplan, Richard; Ledermann, Jonathan A.
Afiliação
  • Clamp AR; Department of Medical Oncology, The Christie National Health Service Foundation Trust, and University of Manchester, Manchester, UK.
  • James EC; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK. Electronic address: e.james@ucl.ac.uk.
  • McNeish IA; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Dean A; Oncology Department, St John of God Hospital, Subiaco, WA, Australia.
  • Kim JW; Department of Obstetrics and Gynaecology, Seoul National University, Seoul, Korea.
  • O'Donnell DM; Cancer Trials Ireland, Dublin, Ireland.
  • Hook J; St James' University Hospital, Leeds, UK.
  • Coyle C; Queen Alexandra Hospital, Portsmouth Hospitals National Health Service Trust, Portsmouth, UK.
  • Blagden S; Churchill Hospital, University of Oxford, Oxford, UK.
  • Brenton JD; Li Ka Shing Centre, Cancer Research UK Cambridge Institute, Cambridge, UK.
  • Naik R; Gynaecology Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK.
  • Perren T; St James' University Hospital, Leeds, UK.
  • Sundar S; Institute of Cancer and Genomics, University of Birmingham, Birmingham, UK.
  • Cook AD; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
  • Gopalakrishnan GS; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
  • Gabra H; Department of Surgery and Cancer, Imperial College London, London, UK; Early Clinical Development, AstraZeneca, Cambridge, UK.
  • Lord R; Department of Oncology, Clatterbridge Cancer Centre, Wirral, UK.
  • Dark G; Northern Centre for Cancer Care, Freeman Hospital, Newcastle, UK.
  • Earl HM; Department of Medical Oncology, Addenbrooke's Hospital, Cambridge, UK.
  • Hall M; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
  • Banerjee S; Gynaecological Unit, The Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, London, UK.
  • Glasspool RM; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Jones R; Velindre Cancer Centre, Wales, UK.
  • Williams S; Birmingham City Hospital, Birmingham, UK.
  • Swart AM; Norwich Medical School, University of East Anglia, Norwich, UK.
  • Stenning S; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
  • Parmar M; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
  • Kaplan R; Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London, UK.
  • Ledermann JA; University College London Cancer Institute, and University College London Hospitals, London, UK.
Lancet ; 394(10214): 2084-2095, 2019 12 07.
Article em En | MEDLINE | ID: mdl-31791688
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Peritoneais / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias das Tubas Uterinas / Carcinoma Epitelial do Ovário Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Peritoneais / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias das Tubas Uterinas / Carcinoma Epitelial do Ovário Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies Limite: Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Reino Unido